why choose us

First received: July 24, 2022

Clinical Trial: Non-alcoholic Fatty Liver Disease and Its Treatment

Study Status: Completed

Recruit Status: Completed

Condition: NAFLD

Study Type: Interventional


Official Title: Effect of DPP-4I and Related Treatment on Non-alcoholic Fatty Liver Disease

Brief Summary: Dipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients. A major unanswered question concerns the potential ability of DPP-4I to improve intrahepatic lipid (IHL) content in nonalcoholic fatty liver disease (NAFLD) patients. The aim of this study was to evaluate the effects of sitagliptin on IHL in NAFLD patients.

Read more